Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceramide NanoLiposome in advanced solid tumors
NCT02834611Phase 1Completed
- Sponsor
- PendreaBio
- Start
- Mar 2017
- Primary completion
- Aug 2023
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ceramide nanoliposome in solid tumor, sponsored by PendreaBio. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Mar 2017; status: completed.
02
Drugs
Ceramide nanoliposome
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02834611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834611.